Charles River Laboratories Invests in Autobahn Labs Under Collaborative Deal

MT Newswires Live07-25

Charles River Laboratories International (CRL) has made an investment in Autobahn Labs, joining a fundraising round led by Autobahn's founding investor, Samsara BioCapital, the companies said Wednesday.

They said Charles River will be the preferred research partner for Autobahn's pipeline of early-stage, preclinical therapeutics' programs as part of their partnership. The agreement will also grant Autobahn preferred access to Charles River's drug discovery and development capabilities.

The investment and collaboration will enable Autobahn to expand its partnerships with academic institutions, advance preclinical programs, and identify new opportunities for therapeutics development, the companies said. Justin Bryans, chief scientific officer, discovery for Charles River, has joined Autobahn's board.

Charles River shares were up about 2% in recent trading.

Price: 224.95, Change: +4.67, Percent Change: +2.12

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2454880274?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-25 00:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2454880274","market":"us","top_or_hot":-1,"title":"Charles River Laboratories Invests in Autobahn Labs Under Collaborative Deal","media":"MT Newswires Live","content":"<html><body><p> Charles River Laboratories International (CRL) has made an investment in Autobahn Labs, joining a fundraising round led by Autobahn's founding investor, Samsara BioCapital, the companies said Wednesday.</p><p>They said Charles River will be the preferred research partner for Autobahn's pipeline of early-stage, preclinical therapeutics' programs as part of their partnership. The agreement will also grant Autobahn preferred access to Charles River's drug discovery and development capabilities.</p><p>The investment and collaboration will enable Autobahn to expand its partnerships with academic institutions, advance preclinical programs, and identify new opportunities for therapeutics development, the companies said. Justin Bryans, chief scientific officer, discovery for Charles River, has joined Autobahn's board.</p><p>Charles River shares were up about 2% in recent trading.</p><p>Price: 224.95, Change: +4.67, Percent Change: +2.12</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Charles River Laboratories Invests in Autobahn Labs Under Collaborative Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCharles River Laboratories Invests in Autobahn Labs Under Collaborative Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-25 00:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Charles River Laboratories International (CRL) has made an investment in Autobahn Labs, joining a fundraising round led by Autobahn's founding investor, Samsara BioCapital, the companies said ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7095","symbol_name":"多种金属与采矿","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2454880274","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2454880274","pubTimestamp":1721837752,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Charles River Laboratories International  has made an investment in Autobahn Labs, joining a fundraising round led by Autobahn's founding investor, Samsara BioCapital, the companies said Wednesday.They said Charles River will be the preferred research partner for Autobahn's pipeline of early-stage, preclinical therapeutics' programs as part of their partnership. The agreement will also grant Autobahn preferred access to Charles River's drug discovery and development capabilities.The investment and collaboration will enable Autobahn to expand its partnerships with academic institutions, advance preclinical programs, and identify new opportunities for therapeutics development, the companies said. Justin Bryans, chief scientific officer, discovery for Charles River, has joined Autobahn's board.Charles River shares were up about 2% in recent trading.Price: 224.95, Change: +4.67, Percent Change: +2.12","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7095":"多种金属与采矿","BK4121":"生命科学工具和服务","CRL.AU":"Comet Resources Ltd","BK4585":"ETF&股票定投概念","BK4530":"医药外包概念","BK4588":"碎股","CRL":"查尔斯河","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC"},"translate_title":"Charles River Laboratories根据合作协议投资Autobahn Labs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL":1,"CRL.AU":1},"content_text":"Charles River Laboratories International (CRL) has made an investment in Autobahn Labs, joining a fundraising round led by Autobahn's founding investor, Samsara BioCapital, the companies said Wednesday.They said Charles River will be the preferred research partner for Autobahn's pipeline of early-stage, preclinical therapeutics' programs as part of their partnership. The agreement will also grant Autobahn preferred access to Charles River's drug discovery and development capabilities.The investment and collaboration will enable Autobahn to expand its partnerships with academic institutions, advance preclinical programs, and identify new opportunities for therapeutics development, the companies said. Justin Bryans, chief scientific officer, discovery for Charles River, has joined Autobahn's board.Charles River shares were up about 2% in recent trading.Price: 224.95, Change: +4.67, Percent Change: +2.12","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2454880274"}